Phase 2 WU-CART-007: CD7-targeted CAR-T Cell Therapy for R/R T-ALL and T-LBL

This trial evaluates the efficacy of a single intravenous infusion of WU-CART-007—an anti-CD7 CAR-T cell therapy administered after lymphodepletion—in relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma patients. Sponsored by Wugen, Inc., the study aims to assess composite complete remission and minimal residual disease-negative response, offering new insights into targeting CD7 in these aggressive malignancies.